Abstract
There are some evidences regarding beneficial effects of carnitine in improvement of depression symptoms. Incidence of depression is significantly higher among HIV positive individuals compared to HIV negative populations. Also carnitine deficiency is prevalent in HIV positive individuals.
In a cross-sectional study correlation between serum carnitine level and depression severity based on the Beck Depression Inventory questionnaire was assessed in 100 HIV/AIDS (42 males and 58 females) patients. According to the Beck Depression Inventory definitions, 31%, 16%, and 21% of the patients experienced mild, moderate, and severe depression, respectively.
The mean ± SD serum concentration of total carnitine in the patients was 37.96 ± 26.08 (µmol/L). Fifty-four (54%) patients were categorized as carnitine deficient. A non-statistically significant negative correlation between patients’ depression scores and total levels of serum carnitine was found. Considering the prevalence of depression among HIV/AIDS patients and probable role of carnitine in the pathogenesis of depressive disorders, more studies are needed to reveal correlation between depression and the body storage of carnitine.
Keywords: Depression, carnitine, HIV/AIDS.
Current HIV Research
Title:Frequency of Depression and its Correlation with Serum Carnitine Level in HIV/AIDS Patients
Volume: 11 Issue: 3
Author(s): Haleh Rezaee, Hossein Khalili, Shima Hatamkhani, Simin Dashti-Khavidaki and Zahra Khazaeipour
Affiliation:
Keywords: Depression, carnitine, HIV/AIDS.
Abstract: There are some evidences regarding beneficial effects of carnitine in improvement of depression symptoms. Incidence of depression is significantly higher among HIV positive individuals compared to HIV negative populations. Also carnitine deficiency is prevalent in HIV positive individuals.
In a cross-sectional study correlation between serum carnitine level and depression severity based on the Beck Depression Inventory questionnaire was assessed in 100 HIV/AIDS (42 males and 58 females) patients. According to the Beck Depression Inventory definitions, 31%, 16%, and 21% of the patients experienced mild, moderate, and severe depression, respectively.
The mean ± SD serum concentration of total carnitine in the patients was 37.96 ± 26.08 (µmol/L). Fifty-four (54%) patients were categorized as carnitine deficient. A non-statistically significant negative correlation between patients’ depression scores and total levels of serum carnitine was found. Considering the prevalence of depression among HIV/AIDS patients and probable role of carnitine in the pathogenesis of depressive disorders, more studies are needed to reveal correlation between depression and the body storage of carnitine.
Export Options
About this article
Cite this article as:
Rezaee Haleh, Khalili Hossein, Hatamkhani Shima, Dashti-Khavidaki Simin and Khazaeipour Zahra, Frequency of Depression and its Correlation with Serum Carnitine Level in HIV/AIDS Patients, Current HIV Research 2013; 11 (3) . https://dx.doi.org/10.2174/1570162X11311030007
DOI https://dx.doi.org/10.2174/1570162X11311030007 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurogenic plasticity of mesenchymal stem cell, an alluring cellular replacement for traumatic brain injury
Current Stem Cell Research & Therapy Recent Advances in Neuro-Endocrine-Immune Interactions in the Pathophysiology of Rheumatoid Arthritis
Current Rheumatology Reviews Pluripotency and Targeted Reprogramming: Strategies, Disease Modeling and Drug Screening
Current Drug Delivery Plasticity and Therapeutic Potential of Mesenchymal Stem Cells in the Nervous System
Current Pharmaceutical Design Neuroprotective Role of Natural Polyphenols
Current Topics in Medicinal Chemistry Breathing Generation and Potential Pharmacotherapeutic Approaches to Central Respiratory Disorders
Current Medicinal Chemistry The Honolulu-Asia Aging Study: Epidemiologic and Neuropathologic Research on Cognitive Impairment
Current Alzheimer Research Growth Factors and Astrocytes Metabolism: Possible Roles for Platelet Derived Growth Factor
Medicinal Chemistry Survey of the State of the Art in Biomaterials, Cells, Genes and Proteins Integrated into Micro- and Nanoscaffolds for Tissue Regeneration
Current Nanoscience Induced Pluripotent Stem Cells and Their Potential for Basic and Clinical Sciences
Current Cardiology Reviews Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Stem Cell Patents: An Innovative Approach to Anti-Cancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery White Matter Injury Mechanisms
Current Molecular Medicine Experimental and Clinical Advances in Immunotherapy Strategies for Spinal Cord Injury Target on MAIs and Their Receptors
Current Pharmaceutical Design Gastrin-Releasing Peptide as a Molecular Target for Inflammatory Diseases: An Update
Inflammation & Allergy - Drug Targets (Discontinued) Insulin-Like Growth Factor-1 and its Derivatives: Potential Pharmaceutical Application for Ischemic Brain Injury
Recent Patents on CNS Drug Discovery (Discontinued) Mesenchymal Stem Cell Research in Veterinary Medicine
Current Stem Cell Research & Therapy Marine Food Protection in Testicular Damages Caused by Diabetes Mellitus
Current Diabetes Reviews Therapeutic Antibodies for Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Cyclooxygenase-2 Biology
Current Pharmaceutical Design